Quality control company Rapid Micro raises $120M in equity and debt

Rapid Micro hopes to use its new $120 million debt and equity infusion for commercial expansion of its automated contaminant testing product for drug manufacturers, as well as a new rapid sterility test backed by BARDA.

The series C funding includes an equity round led by Ally Bridge Group, with contributions from new investor Endeavour Vision and prior investors Bain Capital Life Sciences, Longitude Capital, Xeraya Capital and Asahi Kasei Medical...